Structural basis for molecular recognition at serotonin receptors

Science

Volumn 340, Issue 6132, 2013, Pages 610-614

  Wang, Chong ^a   Jiang, Yi ^a,b   Ma, Jinming ^a,c   Wu, Huixian ^a   Wacker, Daniel ^a   Katritch, Vsevolod ^a   Han, Gye Won ^a   Liu, Wei ^a   Huang, Xi Ping ^d   Vardy, Eyal ^d   McCorvy, John D ^d   Gao, Xiang ^c   Zhou, X Edward ^c   Melcher, Karsten ^c   Zhang, Chenghai ^b,c   Bai, Fang ^e   Yang, Huaiyu ^b   Yang, Linlin ^b   Jiang, Hualiang ^b   Roth, Bryan L ^d   Cherezov, Vadim ^a   Stevens, Raymond C ^a   Xu, H Eric ^b,c   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN AGONIST;

CRYSTAL STRUCTURE; DISEASE TREATMENT; DRUG; LIGAND; MOLECULAR ANALYSIS; MUTATION; NITROGEN COMPOUND; PHYSIOLOGY;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISULFIDE BOND; HUMAN; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR RECOGNITION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL;

EID: 84877607189     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1232807     Document Type: Article

References (31)

1. M. Berger, J. A. Gray, B. L. Roth, Annu. Rev. Med. 60, 355 (2009).
2. D. Hoyer et al., Pharmacol. Rev. 46, 157 (1994).
3. B. L. Roth, S. M. Hanizavareh, A. E. Blum, Psychopharmacology 174, 17 (2004).
4. B. L. Roth, D. J. Sheffler, W. K. Kroeze, Nat. Rev. Drug Discov. 3, 353 (2004).
5. W. K. Kroeze, K. Kristiansen, B. L. Roth, Curr. Top. Med. Chem. 2, 507 (2002).
6. M. M. Goldenberg, Pharm. Ther. 37, 499 (2012).
7. B. M. Smith et al., J. Med. Chem. 51, 305 (2008).
8. J. Besnard et al., Nature 492, 215 (2012).
9. B. L. Roth, N. Engl. J. Med. 356, 6 (2007).
10. C. M. Villalón, D. Centurión, L. F. Valdivia, P. de Vries, P. R. Saxena, Curr. Vasc. Pharmacol. 1, 71 (2003).
11. Affected drugs include the antimigraine drugs ERG, DHE, and methysergide (usage limited); the appetite suppressant drugs fenfluramine, dex-fenfluramine, and aminorex (all withdrawn); and some drugs used for treating Parkinson 's disease: pergolide and cabergoline (both withdrawn).
12. R. B. Rothman, M. H. Baumann, Pharmacol. Biochem. Behav. 71, 825 (2002).
13. D. Wacker et al ., Science 340, 615 (2013).
14. Materials and methods are available as supplementary materials on Science Online.
15. Superscripts refer to the Ballesteros-Weinstein numbering, in which the most conserved among class A GPCR residues in each transmembrane helix are designated x.50, where x is the helix number.
16. J. A. Ballesteros, H. Weinstein, Methods Neurosci. 25, 366 (1995).
17. 7.36 - are part of the extended binding site.
18. K. Haga et al., Nature 482, 547 (2012).
19. V. Katritch, V. Cherezov, R. C. Stevens, Trends Pharmacol. Sci. 33, 17 (2012).
20. M. R. Braden,D. E. Nichols, Mol. Pharmacol. 72, 1200 (2007).
21. D. A. Shapiro, K. Kristiansen, W. K. Kroeze, B. L. Roth, Mol. Pharmacol. 58, 877 (2000).
22. S. Mehrotra et al., Naunyn Schmiedebergs Arch. Pharmacol. 378, 371 (2008).
23. H. M. Connolly et al ., N. Engl. J. Med. 337, 581 (1997).
24. R. B. Rothman, Ann. Intern. Med. 136, 779 (2002).
25. R. B. Rothman et al., Circulation 102, 2836 (2000).
26. V. Setola, M. Dukat, R. A. Glennon, B. L. Roth, Mol. Pharmacol. 68, 20 (2005).
27. N. Adham et al., Neuropharmacology 33, 387 (1994).
28. D. L. Nelson, V. L. Lucaites, J. E. Audia, J. S. Nissen, D. B. Wainscott, J. Pharmacol. Exp. Ther. 265, 1272 (1993).
29. D. Oksenberg et al., Nature 360, 161 (1992).
30. V. Cherezov et al ., Science 318, 1258 (2007).
31. T. Warne et al., Nature 454, 486 (2008).